How do breast cancer drugs work in real life? new study digs into medical records

NCT ID NCT06495164

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how Palbociclib and other CDK4/6 inhibitors are actually used in patients with a common type of advanced breast cancer (HR+/HER2-). Researchers will analyze anonymous medical records from routine care to see how long patients stay on treatment and whether it delays the need for chemotherapy. The goal is to understand real-world effectiveness, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Palbociclib (Ibrance), other CDK4/6 inhibitors (Ribociclib, Abemaciclib), and aromatase inhibitors (letrozole, anastrozole, exemestane)
What this could lead to
If successful, this study could provide a clearer picture of how these drugs work in everyday practice, potentially guiding better treatment decisions for patients with this type of breast cancer.
What could go wrong
This is an observational study using existing medical records, not a controlled trial. Results may be influenced by missing data or patient selection, and cannot prove cause and effect.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Pfizer New York

    New York, New York, 10001, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.